Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ridaforolimus - Medinol

Drug Profile

Ridaforolimus - Medinol

Alternative Names: AP 23573; BioNIR; Deforolimus; EluNIR; EluNIR™ Ridaforolimus-Eluting Coronary Stent System; Jenzyl; MedJ-01; MK-8669; NirSupreme

Latest Information Update: 01 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Medinol; Merck & Co
  • Class Antineoplastics; Macrolides; Vascular disorder therapies
  • Mechanism of Action MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Sarcoma
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Coronary artery restenosis
  • Preregistration Submission Withdrawal Sarcoma
  • Discontinued Breast cancer; Cancer; Endometrial cancer; Neurodegenerative disorders; Non-small cell lung cancer; Ovarian cancer; Prostate cancer; Renal cell carcinoma; Solid tumours

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 15 Mar 2018 Merck completes a phase II trial in Breast cancer (Combination therapy, late-stage disease, Metastatic disease, Second-line therapy or greater) (NCT01605396)
  • 04 Feb 2018 Merck and Ariad terminates a phase II extension trial for Solid tumours (In infants, In adolescents, In children, In adults) in USA (NCT00836927)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top